That's the dumbest post you've made so far. Going to jail? We all lost a lot in Todos. I welcome a SEC investigation if you can convince them to conduct one. I have a decade of experience dealing with government regulators. Bring it on. Truth always wins, vs. ignorant speculation.

My reaction:

Link to video of FDA Vaccine and Related Biological Products Advisory Committee Meeting held on June 5, 2024.

Yet, you continue to reply to my posts. We both know MONI is a Pump and Dump scam. Only one good use for MONI as an investment. Not a great strategy.

Link to 2024 Jeffries Global Healthcare Conference. Registration is required, but you can use any name and email address ( i.e., Johnny Peckerhead / Fake Analyst / JPeckerhead@aol.com) if you want to keep yours off their marketing email list. Novavax presentation begins at 12:30 Eastern.

Should be time well spent. Audio will be available on Novavax website for 30 days following conference. Click Virtual webcast to access the site.

https://ir.novavax.com/events#nav

First-gen mRNA flu vaccines 'will not win,' Sanofi execs admit as they retool strategy

FIERCE Biotech
June 30, 2023

https://www.fiercebiotech.com/biotech/first-gen-mrna-flu-vaccines-wont-win-sanofi-execs-admit-they-retool-strategy

Interesting read. This explains why they partnered with Novavax for Matrix-M. I expect we will see additional partnerships for Matrix-M announced with other biotechs in the coming months.

$ $ $

NEWS: Novavax Prepared to Deliver JN.1 Protein-based Non-mRNA COVID-19 Vaccine This Fall Consistent with U.S. FDA VRBPAC Recommendation

https://ir.novavax.com/press-releases/Novavax-Prepared-to-Deliver-JN-1-Protein-based-Non-mRNA-COVID-19-Vaccine-This-Fall-Consistent-with-U-S-FDA-VRBPAC-Recommendation

June 5, 2024

Today the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend that COVID-19 vaccines be updated to a monovalent JN.1-lineage composition for 2024-2025 and expressed a preference for the JN.1 strain. The Committee acknowledged the importance of having a protein-based option available at the start of the vaccination season, alongside other alternatives. Novavax expects to be ready for the commercial delivery of a protein-based JN.1 COVID-19 vaccine in the U.S. in September this fall, pending authorization.

The Committee acknowledged the advantages of a JN.1 vaccine in providing broad protection against circulating and future strains, based upon data presented by all manufacturers, and the need to minimize confusion in making public health recommendations. Novavax’s JN.1 COVID-19 vaccine has demonstrated broad cross-neutralizing antibodies for a range of JN.1 descendant viruses, including KP.2 and KP.3. We believe updating to the JN.1 lineage or JN.1, as recommended by the World Health Organization and the European Medicines Agency and as unanimously recommended by VRBPAC today, will provide the protection needed this fall against COVID-19.1,2

Our most recent nonclinical data have demonstrated that our JN.1 vaccine candidate induces broad neutralization responses to JN.1 lineage viruses including those with the F456L mutation (e.g., JN.1.16), the R346T mutation (e.g., JN.1.13.1), to “FLiRT” variants that contain both mutations such as KP.2, currently the most common circulating variant in the U.S., and to “FLuQE” variants that are increasing in circulation (e.g., KP.3).1,3,4 Our JN.1 vaccine candidate also produces conserved polyfunctional, Th1-biased CD4+ T cell responses to a range of JN.1 lineage variants including those containing the F456L, R346T and FLiRT mutations (e.g., KP.2).1 These responses indicate that our vaccine technology induces broadly neutralizing responses against multiple variant strains, including to circulating forward drift variants.

JP, I know you'll be happy to learn I'm within about $10K of fully recovering my Todos loss. I have to give a SHOUT OUT to GC for pointing me in Novavax's direction. He fully understood the issues with the mRNA Covid vaccines long before most others, and gave great insight by recommending Nuvaxovid, which got me to take a closer look at the company making it.

Even though I don't try to pass myself off as a stock analyst like some do, perhaps you could invest in NVAX and recover some of your losses in AMBS, MONI, IBIO, etc. etc. We could even provide you with Gerald's current email address so you could thank him personally for steering us (and yourself) toward this great little biotech company. I'm confident Gerald is invested in NVAX as well.

CONGRATULATIONS to other TOMDF investors who were smart enough to follow Gerald's posts on X and take a position in NVAX. We have a lot of great things ahead of us as investors. Here's news from the FDA Advisory meeting today.

https://ir.novavax.com/press-releases/Novavax-Prepared-to-Deliver-JN-1-Protein-based-Non-mRNA-COVID-19-Vaccine-This-Fall-Consistent-with-U-S-FDA-VRBPAC-Recommendation

I expect my TOMDF loss will be fully behind me by closing price tomorrow, and certainly by Friday's close. I'll keep you posted, JP.

Yeah, I took a loss on the MONI sale. Dumb move on my part for even buying the shares. Glad I got out of this 💩 that's going nowhere. On the other hand, my NVAX investment is up over $60K today, while some invest here for a decade and like to think of themselves as savvy investors while flipping pocket change.

I like to make money, but that's not happening with MONI. 💩

I'm so glad I sold this MONI turd 💩 at .053 and invested in a reputable company that is already showing multiple six-figure gains. Some here have been pumping this 💩 for a decade and it's still in the toilet. Time to FLUSH.

Agreed, Gerald recommended Novavax and I can't thank him enough for pointing me to this great company, and their superior Covid vaccine. It's been on a real rip since the Sanofi partnership was announced. It sure beats some investors strategy of waiting for decades their penny stocks P&Ds to make them some MONI. 😎




On this investment alone, my Todos Medical losses are about to be history. Appreciate the head's up, GC. 👍️ Almost there. Share price continues higher in after-hours trading.




No Fugazi here...

Now, now, JP... you should know very well the saying, "Da Nile is not just a river in Egypt". You also know I can back up everything I've claimed, directly from my very real Fidelity accounts. LMAO

And again, it was GERALD who pointed me to Novavax. That's gotta sting a little, or a LOT. 🤯

I exited my entire Todos Medical position of 75.8M shares Feb 5 - 8, 2024. Publicly available trading volume data will support this. All trades were executed between the range of $0.0001 - $0.00012. This was when trading volume was still high and before trading dried up to almost zero.

These are the Todos Medical trade summaries from my four Fidelity accounts holding Todos shares. I was able to recover $7,990 and change, and every cent was reinvested in Novavax.









These are my Novavax holdings across four Fidelity accounts, with the first half of each account number revealed, direct from Fidelity's website, based on closing share price on 5/22/24.



Here's the Excel break-even analysis price. The 52-week high share price was reached on 5/22/24. Getting closer and closer to the break-even price calculated below. 😃 The large short position in NVAX is also helping to drive the price higher as some short positions are starting to see heavy losses. However, this is a long-term hold for me. I expect the company to be acquired within the next 2 years.



I can back up my claims. Mark this post: I will recover every penny of my Todos loss with Novavax. Continue living in denial if that makes you feel warm and fuzzy. But we all know the real reason, don't we?

Maverick at the controls of this stock price.

JPetro, another update on my investment, but changing one number from the previous post.

When my Novavax investment reaches $21.55 per share, the value of the shares will be equal to the amount invested + recoving my entire loss in Todos Medical. That price is coming soon. Latest closing price was $14.91.

Guess who turned me on to Novavax as a vaccine and potential investment? Gerald Commissiong
👍️👍️👍️👍️👍️

I know you are cheering for me. 😎

For your enjoyment, JPetro...

1. When my Novavax investment reaches $19.90 per share, the value of my shares will be equal to the cost of the NVAX shares + my ENTIRE loss on my Todos investment.

2. NVAX closed at $14.79 today, up 13.7% and well above my cost basis of $5.34 per share, which includes the $7,990 recovered from sale of my TOMDF shares over four days in February, as previously posted.

3. Guess who turned me on to Novavax as a vaccine and potential investment? Gerald Commissiong 👍️

The $500M initial Sanofi payment is due Monday, May 20. We should see a PR and/or SEC 8-K filing this week.

I expect news of additional partnerships or licensing agreements for Matrix-M adjuvant over the coming weeks and months.

What does being underwater have to do with one's ability to sell? I exited my Todos position over a 4-day period as previously posted. Rolled the proceeds into NVAX which is doing wonderfully, since almost all of my shares were purchased prior to the Sanofi partnership. When NVAX reaches $20 I will have recovered my entire loss in Todos. That will occur in the next few weeks or months. Mark this post.

I also received the Novavax Covid vaccine last fall. Many thanks to Gerald Commissioning for making me aware of the Novavax Covid vaccine and its advantages over the mRNA vaccines from Pfizer and Moderna, and to consider the company as an investment. Hard to have negative feelings for GC when he provided the solution for maximum Covid protection and a means to recover ALL of my Todos losses. I only had to do the DD on Novavax and make the choice to invest.

Thanks, GC!!

As more people listen to the Novavax presentation at the Bank of America 2024 Healthcare Conference, there will be more new investors buying in for the first time, and current investors adding to their existing positions. I expect to see NVAX share price climb higher. We'll get news updates in between earnings that will add fuel to the fire. I don't believe Sanofi is going to be the only partner we sign this year. Another partner with a similar up-front cash and royalty deal will light the fuse on the second rocket engine, with the first rocket engine ignited by the Sanofi deal. Great time to be a NVAX shareholder.

The BoA conference presentation yesterday is really worth a listen. The BoA analyst did a great job with the questions and investors learned more about the incredible benefits of the Sanofi partnership. I feel fortunate to be an investor here.

Webcast link

May 2024 Investor Presentation - Not part of BoA presentation but recommended

When is the next reverse split for IBIO? That would make 4 in only a few years, right? Will they adjust the authorized shares this time along the RS ratio? Or keep authorized shares the same and make this a fantastic ATM machine for management, at the expense of shareholders? This investment is and has been a 💩 for a long time, although still recommended and purchased by some fake stock analysts with very poor investment track record. No zip code changes yet in that couple of decade long portfolio. 🙀

Not disappeared. Sold and moved on. Already up $128K on another investment since exiting Todos. I'll easily recover my Todos losses because I don't let one bad investment define me and impact my future investments. You won't see me 😭 about my losses here years afterwards like some.

Accepted responsibility for your decisions yet? Didn't think so.

Have some pizza. Still waiting for those Dominos IT sleuths to nail me. Didn't work out that way, huh? Maybe because it wasn't me at all like you claimed. No better at that than stock picking.

SEC filings are all that count, according to one fake financial analyst with a long history of picking turds. Except the rule doesn't apply to MONI. How could it? MONI uses several methods to communicate with shareholders, typically with shady characters making ridiculous claims on social media. Hypocrisy at the higher level since the standard doesn't apply here. Glad I sold this 💩 a long time ago. It was a scam then and is still a scam. Only noobs and PnD scammers pumping this.

According to the fake stock analyst who posts here, nothing matters except SEC filings... but that doesn't seem to apply when we're talking about MONI. Shady rumors from shady characters posted on social media is taken at face value with no SEC filings and no actual follow-through to support the claims. The rules and advice given on other boards DO NOT APPLY here. How could they? Anyone with a working brain realizes this company is a complete sham. Only the gullible and noob investors are buying or holding shares in MONI, waiting for the inevitable FANTASTIC ACQUISITION that will CHANGE ZIP CODES.

Never gonna happen.

In other news. I'm up over $160K in another investment in the last few days.

Today's Sanofi partnership news and subsequent rise in share price likely generated a significant number of margin calls for shorts. Demand for shares should be pretty high next week to cover today's margin calls. Any movement higher will generate even more margin calls. Great time for a big short squeeze. Thanks shorties for the cheap shares I was able to pick up over the last few months.

Added another 550 shares, now at 17,700 @ $5.32 average cost.

Exciting times ahead for Novavax. Looking forward to seeing what this Sanofi partnership brings to shareholders.

Looking at Wikolo reviews on the Apple App Store, looks like five 5-star reviews, all about one year ago. Nothing since then. Seems very fishy, like insiders and their friends posting reviews trying to gain traction. Almost all other 5-star apps have a ton of reviews and even recent ones, as people are drawn to great apps. IMO with no new reviews in the last 12 months, no one really wants this app. Maybe MONI will hire those crack BitGift programmers to help revamp Wikolo into something people will want? God help them.

MONI once again holding out the carrot for noob investors who believe this will be a great product. BitGift was a great product too, according to these gullible investors. Glad I sold this 💩 at 0.053 and took only a small loss. Look at today's price. BUY BUY BUY!!! says the fake stock analyst. BAF MONI. LMAO

On a brighter note, my Novavax shares up over 130% today on news of Sanofi partnership.

Same here. 17,150 shares at average cost of $5.17. The partnership announced today negates all of Shah's concerns. I'm revising my votes.

The fake stock analyst may have more to worry about than his IBIO and MONI investments. I hear rumors the SEC gonna come calling. They now have the full audio files of both recordings where the fake analyst was sputtering and stammering like a buffoon. I wonder if they will buy the excuse that the host made an error, and the fake analyst didn't know how they would use his company name when he provided it. See, that might work for the first call, but the buffoon provided his company name AGAIN a year later on the second call. That excuse won't work for the second violation.

And then there's the records of the conference calls the fake analyst called into, again providing his company name JWP Incorporated, and didn't get selected on the Q&A part. I wonder how many of those calls exist that we don't even know about. SEC will get to the bottom of it. All the IMO's and other lame statements attached to postings here won't matter.

Whose gonna come knocking at the door first? JFB or the SEC. Maybe both at the same time? Wouldn't that be a riot. Of course, full video would be posted on all the boards where the fake analyst posts. I also heard from a friend that the fake analyst was likely in contact with Mr. Napadano, the analyst who covered AMBS who went to prison for fraud. SEC looking into that report as well. Fake analyst says he's contacted a detective regarding my post to come to NJ for a visit. He might be better off contacting his attorney. But he's too brash for that. Ooh-Rah!

Wishing a Happy Easter to IBIO investors. I hope your investment here is successful. Beware of anything posted by the fake analyst from JWP Inc. Follow his posts and see a dismal track record of investment success. Pretty much no success anywhere, ever. That $20K initial investment in IBIO prior to the 3 RS's is typical. You might want to reconsider investing in IBIO if this clown is invested here and pumping the stock.

Fake analyst buffoon claims this is me. There are a few problems:
1. I don't live in Miami and never have.
2. Wrong eye color.
3. I'm not bald and don't shave my head.



3 strike strike-out. Or 3 more 💩 thrown at a wall to see if something sticks. Massively incompetent DD this fake analyst churns out. If I had a dollar for every person he claims me to be... I could buy some IBIO and MONI and wait for that investment to turn into about 1.2 cents. 🙀

I thought I was Warp. Now you're claiming I am MiamiMark? Are we all the same person? I see you continue to throw more of your turds 💩 at the wall hoping something will stick.

Red and I take great pleasure in reading your ridiculous claims. The lack of any real analytical or investigative skills is stunning, especially with multiple investor calls trying to sound like an analyst. That's the crown jewel. MULTIPLE CALLS. Yeah, they made an error, right? LMFAO

Share price only has to get back to $20,000 per share for someone who bought 5000 shares at $4 (adjusting for the 3 reverse splits since then) to break even. Those 5000 shares were reduced to 500 shares, then to 20 shares, then to 1 share. All the while the buyer was posting BUY BUY BUY on this board. Maybe the buyer averaged down and now only needs $2,000 per share to break even.

Good to be excited about the stock again after many months of silence, I suppose. 💩

Glad I sold this MONI turd 💩 at 0.054. Didn't take long to discover MONI is a P&D Scam.

Clearly there are issues for you reading a statement and understanding it. You keep highlighting the same text that doesn't answer the question posed.

Where exactly in my post do I say anything about fake IP address, burner phones, or multiple aliases. The only thing mentioned is fake credentials (name and email address) and I stated reason why.

The rest of it you're pulling out of your ASS.

That's it. The last one. You can't provide an accurate or intelligent answer, so you keep throwing the same turd at the wall to see if it will stick. Kinda like how you make investment choices. 💩 💩 💩 None sticking for last 10 years. No zip code change for you.

So, just from a practical standpoint, if I was going to acquire that many shares, the very LAST thing I'd do is announce it publicly to a bunch of investors. If the intent was real, acquiring that position under the radar would results in less of my money invested to acquire the position. No one wants to overpay for shares when they don't have to. One would expect the increased demand to move the share price higher, but not as high as adding in the demand from a bunch of message board readers who conclude they can mortgage the house and make a fortune on MONI shares.

That alone should be enough for the reasonably intelligent person to realize this is a pump and dump scam. No one in a position to acquire that many shares would announce it that way prior to the transactions. Only fools and naive investors would fall for it, their reasoning clouded by their visions of $$$ and zip code changes.

As one unlicensed analyst from JWP Incorporated would put it: BUY BUY BUY!!!. and MONI will surprise.

MONI surprised all right. My condolences to those who followed that advice. 💩

Where exactly in my post do I say anything about fake IP address, burner phones, or multiple aliases. The only thing mentioned is fake credentials (name and email address) and I stated reason why.

The rest of it you're pulling out of your ass. And you have no clue about VPNs and IP addresses. Did your crack IT team at Dominos ever discover who was sending you pizzas? Why haven't you updated us on that?

MiamiMark (whoever the f*ck that is)... how is that relevant? Your new infatuation, perhaps? Kicked GC to the curb? Maybe it was this guy sending the pizzas?

The analyst from JWP Incorporated believes the current MONI share price is a great opportunity to BUY BUY BUY!!! The added support in MONI might even drive it back over 1 cent.

MONI definitely will be a zip code changer, depending on how much you invest here. Problem is, it's not gonna be a zip code you would want to move into. Figure it out.

The rumor mill indicates the JWP Inc analyst is setting up a Come To Jesus call with the MONI CEO, after which many current shareholders will be contacted and urged to BUY BUY BUY. There will be some reference to WHALES coming in take the share price much higher. Figure out the motive here.

That's always the deal with MONI, isn't it? After each "new thing" or "new acquisition" fails miserably, the pumpers move on to the next shiny new object as the future of MONI. It must suck to still be trolling that same line a decade later. But hey, keep throwing turds at the wall to see if any stick. Great game plan.

Bought any CRYTPO lately using BitGift? LMAO. Where's the revenue from that game change? Did MONI forget to include it in the "audited" filings?

The question that is never answered is this:

Why provide your company name again on the second investor call, if you claim that caused the error on the first investor call?

A. I forgot about the first call where I was presented as an analyst.
B. They made the mistake AGAIN on the second call. Gerald should have corrected it. It's all his fault.
C. I wanted to be presented as an analyst again. I liked the feeling of importance from the first call.

The facts support answer C. The first call could have been a mistake. The second call definitely was not a mistake. It was intentional because the caller already knew how he would be presented on the call if he provided his company name in lieu of informing the host he was a private investor, as other private investors had done.

Here's an article I found in The Wall Street Journal. Does this sound like someone you've heard on an investor earnings call? On perhaps multiple calls?

https://www.wsj.com/articles/SB120301945499169247

Analyze This: Hoaxer Haunts Earnings Calls
By Betsy McKay
Feb. 16, 2008

Some big companies have had a surprise during their earnings conference calls this quarter -- and it has nothing to do with the weak economy.

At least seven times just the past three weeks, a mystery caller has cleverly insinuated himself into the normally well-manicured ritual of the quarterly calls. As top executives of publicly traded companies respond to securities analysts' questions about their balance sheets, he impersonates a well-known analyst to get called upon. Then, usually declaring himself to be "Joe Herrick of Gutterman Research," he launches into his own version of analyst-speak.

"Congratulations on the solid numbers -- you always seem to come through in challenging times," he said to Leo Kiely, president and chief executive officer of Molson Coors Brewing Co., on Feb. 12, convincingly parroting the obsequious banter common to the calls. "Can you provide some more color as to what you are doing for your supply chain initiatives to reduce manufacturing costs per hectoliter, as you originally promised $150 million in synergy or savings to decrease working capital?"

Analysts say the caller's questions, though credibly phrased, are too off-target for a real analyst. It's more like "consultant-speak," says a disdainful Bryan Spillane, a Banc of America Securities analyst, a victim of one of Mr. Herrick's impersonations. Analysts deal with often-wonky financial details, but "savings per hectoliter" rarely comes up.

But many CEO's have had more trouble telling the difference. Most have gamely tried to answer the questions. Mr. Kiely and two other Molson executives stuck politely with the caller through three detailed follow-ups. Timothy Wolf, the company's global chief financial officer, closed by telling him, "We think we will have some more positive encouraging things to share with you next month in New York," according to a transcript of the call. A Molson spokesman said that to him the caller sounded legitimate at the time.

Executives at PepsiCo Inc., Dean Foods Co., Newell Rubbermaid Inc. and others have had similar experiences since around mid-January. The caller first gives a familiar name to conference-call operators to earn a turn speaking in the calls -- in which dozens of listeners can dial in, but typically just a handful of analysts known to the company get to ask questions. When he's called upon, he corrects the conference-call operator and identifies himself as Joe Herrick (or Harrick in one transcript). He says he is from a firm called Gutterman Research, or in one case Vladimir Research, according to transcripts provided by Thomson Financial.

Analysts and companies contacted about the caller are stymied as to who he could be. Searches using several potential spellings failed to turn up the name or firms on a Financial Industry Regulatory Authority database of registered securities firms and brokers, or on the Securities and Exchange Commission's Investment Adviser Public Disclosure Web site. A Google search found transcripts of several earnings conference calls in which Mr. Herrick has participated. A New York City telephone number used by the caller to phone into one conference call, and obtained by The Wall Street Journal, disconnects immediately when dialed. Of course, Mr. Herrick could still pop up and prove he is for real.

Meanwhile, annoyed executives and analysts are wondering why someone would want to play a game with dry business calls that normally follow a tightly controlled formula -- unless the game is the whole point. They can't figure out how the caller is getting any benefit from so closely mimicking them. "If he was spoofing I would hope he'd be funnier," says Bill Schmitz, an analyst at Deutsche Bank Securities.

Word of the impersonations has been slow to spread. Mr. Schmitz outed the caller on Newell Rubbermaid's Jan. 31 call, having already heard him several times going back to mid-January. Yet the caller was still using other names to get access as late as Thursday, in a call with Jarden Corp. Yesterday, a caller gave a different name and firm, Mindful Capital Investments, on a call with Hormel Foods Corp., but sounded as if he were reading from a similar script. Mr. Herrick's questions are usually narrowly focused on details of a company's results from well-known cost-savings techniques such as "lean management" and Six Sigma, or else supply-chain issues. They're virtually the same on each call, and he often follows up aggressively.

In the Newell Rubbermaid call, Mr. Herrick asked the company's president and chief executive, Mark Ketchum, to outline his "top initiatives regarding lean manufacturing" and Six Sigma. Afterward, Mr. Schmitz came on and warned the executives.

"Hey guys. First, this guy, Joe Gutterman [sic], every conference call this quarter, he logs on as somebody's name and asks these crazy efficiency questions," he said. "So going forward keep in mind you should just disconnect him when he dials in. This is like the sixth call in a row he's done that. It's really annoying." Mr. Schmitz speculates that Mr. Herrick is "some minion" at a consulting firm trying to do clandestine research on companies' use of Six Sigma techniques.

"Our quarterly earnings calls are key opportunities to us to interact with the investment community and to explain our results," says a Newell Rubbermaid spokesman, David Doolittle. "Anyone who would come on the call and use some of that time unproductively is disruptive."

Some companies are now on the alert. Coca-Cola Co. executives listen to the calls of PepsiCo, and they heard Mr. Herrick bombard PepsiCo Chairman and CEO Indra Nooyi on her Feb. 7 call. So Coke gave select analysts a secret password to use to ask questions during its own call Wednesday -- "Diet Coke" -- according to analysts who participated in the call. A Coke spokesman wouldn't comment on steps the company took beyond saying it was "prepared for this and had a contingency plan in place."

Coke's caution was evident when Banc of America's Mr. Spillane, the earlier impersonation victim, posed a detailed question about how much of the company's currency-neutral operating profit growth was organic rather than coming from acquisitions or cost savings. "We hesitated on you for a minute because as we take these questions we are just trying to make sure that in fact you are who you say you are," Coke's chief financial officer, Gary Fayard, said before launching into an answer. "I am the real deal," Mr. Spillane replied.

PepsiCo, not to be outdone by Coke, says it's tightening its screening process to ensure callers are legitimate. "If we find out differently they will be cut off immediately," says a PepsiCo spokesman.

While competition to get into the question queue is keen for a call hosted by PepsiCo or other large corporation, because many analysts and investors dial in, getting to ask a question on a smaller company's call is easy. That makes some of Mr. Herrick's impersonations even stranger, says Bill Pfund, vice president of investor relations for WMS Industries Inc., a slot machine maker in Waukegan, Ill. "It's an open forum," he says. "If you have a question, just come in under your name." It's also unusual for someone to participate in calls for such a broad swath of industries, from beverages to slot machines.

In WMS's conference call Feb. 6, Mr. Herrick asked president and CEO Brian Gamache about "operational improvement initiatives revolving around lean and Six Sigma," according to a transcript. "You always [seem] to come through in a very challenging time," he made sure to say in conference-call style, applauding the company's "good results."

Mr. Herrick's continued appearance on conference calls is becoming a running joke in the analyst community, says John Faucher, a beverage analyst with J.P. Morgan, whose place Mr. Herrick took in the PepsiCo call. Mr. Faucher, who has been keeping tabs on the caller by instant messaging with clients, took a sort of revenge by spoofing Mr. Herrick in a research note following Coke's earnings call on Wednesday. "The only real disappointment on the Coke call was not hearing about their 6 sigma and RONA policies," he wrote.

Mr. Herrick is giving analysts another reason to look forward to a big conference many of them plan to attend in Boca Raton, Fla. next week. Says Mr. Faucher: "One of the big questions is, will Joe Herrick from Gutterman Research show up?"

As shown in your post, some MONI bag holders are still here 10 years later, enduring numerous name and ticker symbol changes in that decade, but still hard at work posting about the company.



Question: Has MONI ever generated one penny of revenue under any prior ticker symbol? We know the answer for the current symbol. Why would anyone hang around for a decade pumping this turd? 💩

Oh, that's right... Zip Code changer. LMAO 🤣

MONI investors are patiently checking their accounts waiting on company 8-K filings for planned mergers and acquisitions. Gotta admire their loyalty, despite the failure of ALL previously announced mergers and acquisitions.

And let us not forget BitGift, which was going to revolutionize the gifting of CRYTPO. LMAO What happened to the announced sale of BitGift? Did that ever complete? They buyer probably backed out once they visited the website and saw how lame and unsecured it turned out to be. Who would want to buy that? So much for the "crack" BitGift programmers often praised on this board. With only $500 on the books, MONI certainly got the best they could afford.

OOH-RAH!! MONI

Your list of analysts covering Amarantus Biosciences is incomplete. After listening to multiple Amarantus conference calls provided to me by former AMBS investors (thanks again for your support), the following analysts were identified on the calls. You will note that there were 4 analysts on the calls NOT on the lists of analysts you provided. They are identified in red. Par for the course with inadequate DD on your part. I would be happy to post the audio files from the conference calls if necessary.

I also included your name for the calls where you presented yourself as an analyst. All other callers who were private investors identified themselves as such. One has to wonder why you didn't identify yourself as a private investor. One could understand the mistake on the November 2013 call, where you posted you didn't know they would announce your company name on the call, or identify you as an analyst. This might have been your first investor conference call, but the call was posted on the AMBS board and the transcript of the call made available that listed you as an analyst. Yeah, okay, their mistake, right?

But on the September 2014 call you once again you identified yourself with your company name, knowing they would identify you as an analyst on the call. Why create the same "error" again unless it was intentional—you wanted to be identified as an analyst. Mistake the first time? Maybe. Mistake the second time? No one is buying that. The SEC is not likely to see it as a mistake repeated a second time one year later. I think they'll come to the same conclusion reached on this board.

April 2013 AMBS Conference Call
Jason Napodano — Zacks Investment Research
Matthew Margolis — OneMedPlace Global Investments

November 2013 AMBS Conference Call
Jason Napodano — Zacks Investment Research
John Petrosino — JWP Incorporated

April 2014 AMBS Conference Call
Jason Napodano — Zacks Investment Research
Nick Cooper — Edison Investment Research
Jeffrey Kraws — Crystal Research Associates

September 2014 AMBS Conference Call
Jason Napodano — Zacks Investment Research
John Petrosino — JWP Incorporated
Jolene Furdek — Edison Investment Research

The fact your name doesn't appear on your list of certified analysts means nothing. The four analysts I identified from the calls (but not on your list) are also FINRA licensed and were clearly interested in Amarantus. More evidence for the SEC looking into this matter. I would be concerned if I were in your shoes.

One other point. From listening to these calls and the numerous Amarantus corporate advisors, it was clear to me this company wasn't the scam you claim. They were very engaging and extremely knowledgeable in their respective fields of expertise. CEO Gerald Commissiong might have made bad choices in funding the company, but it was clear he assembled a top-notch team. I believe he was also on the right track with Todos Medical. But small companies face a lot of hurdles and neither company survived. I lost money in Todos and I own the decision to invest. I don't put all the blame on the CEO, as some do. Anyone who decides to invest 6-figures-plus in a penny stock company with zero revenue has only themselves to blame for that decision. They can either OWN IT, or act like a CRYBABY and blame others.